ANALISIS EFEKTIVITAS DAN KUALITAS HIDUP (UTILITY) PENGGUNAAN GABAPENTIN PADA PASIEN NYERI NEUROPATIK POST STROKE DENGAN DIABETIK NEUROPATI DI RSUD PROVINSI NTB

  • Nurul Qiyaam
  • Wirawan Adikusuma
  • Tri Murti Andayani
  • Dwi endarti
Keywords: nyeri neuropatik, gabapentin, intensitas nyeri, EQ-5D-3L, EQ-VAS

Abstract

ABSTRAK

 

                        Nyeri neuropatik merupakan penyakit kronis yang memerlukan penanganan relatif lama, sehingga dapat mengganggu kualitas hidup (utility) pasien. Penggunaan gabapentin dalam mengurangi intensitas nyeri pada pasien nyeri neuropatik post stroke dengan diabetik neuropati masi kontoversial. Penelitian ini dilakukan untuk menganalisis efektivitas dan kualitas hidup  penggunaan gabapentin pada pasien nyeri neuropatik post stroke dan diabetik neuropati. Pengumpulan data dilakukan selama Mei –Juli 2017. Metode penelitian Quasy Eksperimental Design (two group pre-post test) kemudian dilakukan analisis efektivitas dan kualitas hidup (utility) masing-masing kelompok. Pengukuran efektifitas terapi gabapentin dilihat dari penurunan intensitas nyeri menggunakan Numerical Rating Scale (NRS) yang dikombinasi dengan Visual Analog Scale (VAS) sebelum dan 4 minggu sesudah terapi. Pengukuran kualitas hidup pasien diukur dengan kuesioner EQ-5D-3L dan kuesioner EQ-VAS sebelum dan 4 minggu sesudah terapi. Hasil penelitian menujukkan bahwa penggunaan gabapentin dalam menurunkan intensitas nyeri  pada pasien nyeri neuropatik post stroke dengan diabetik neuropati efektivitasnya sama ditunjukkan dengan hasil analisis statistik (P>0,05). Penggunaan gabapentin dalam  meingkatkan kualitas hidup pada pasien nyeri neuropatik post stroke dengan diabetik neuropati efektivitasnya juga sama ditunjukan dengan hasil analisis statistik (P>0,05).

References

Andayani TM, : Farmakoekonomi :prinsip

dan metodologi, Bursa ilmu,

Yogyakarta: 2013

Attal N, Cruucu G, Haanpaa M et al. EFNS

Task Force, EFNS guideline on

pharmacological treatment of

neuropathic pain, Eur J Neurol

revision 2010.

Berger A, Dukes E, Oster G. Clinical

characteristics and economic cost of

painful neuropathic disorder. J Pain

Bootman JL, Townsend RJ, Ghan WF.

Principles of pharmacoeconomics. 3rd

ed.USA: Harvey Whitney Books

Company; 2005

Bennett MI, Attal N, Backonja MM. Using

screening tools to identify neuropathic

pain, Pain, 2007.

Bouhassira D, Lanteri Minet M, Attal N,

Laurents B. Prevalence of chronic pain

with neuropathic characteristic in the

general population. Pain 2008

Blair H. Smith & Nicola Torrance:

Epidemiology of Neuropathic Pain

and Its Impact on Quality of Life

Springer Science Business Media,

LLC 2012

Dworkin RH, O Connor AB, Backonja M.

Pharmacologic management of

neuropathic pain: evidence based

recommendations. Pain 2007.

Dupere D. Neuropathic Pain: An Option

Overview. The Canadian Journal of

CME February 2006.

Gilron I, Watson CPN, Cahill CM, Moulin

DE. Neuropathic Pain: A Practical

Guide For The Clinician. CMAJ

August 2006.

Galuzzi KE. Management of Neuropathic

Pain.JAOA September 2005.

Hansson P, Haanpaa M. Diagnostic

workup of neuropathic pain:

computing using questionnaire or

examining the patients?. Eur J Pain

Haanpaa M, Treede RD. Diagnosis and

classification of neuropathic pain,

Pain: Clinical Updates 2010.

Ilsee, WK. Neuropathic: Mechanisms,

Diagnosis, and Treatment. The

Canadian Journal of CME February

Indonesian Eurocol-group EQ-5D, 2003

Meliala L,.Terapi Rasional Nyeri :

Tinjauan khusus Nyeri neuropatik,

Aditya media, Yogjakarta. 2004.

Moore RA, Derry S, Aldington D, Wiffen

PJ: Amitriptyline for neuropatic pain

and fibromialgia in adults (review),

The cochrane library 2012, issue 12

Maroszeky N. SF-36 ® Health Survey

(Version 1.0). Aust Aust Heal

Outcome Collab. 2014;1–15.

National Institute for Health and Clinical

Excellence (2010) Neuropathic pain:

the pharmacological management of

neuropathic pain in adults in nonspecialist

settings. London: National

Institute for Health and Clinical

Excellence. Available from:

www.nice.org. Accessed 10th

September 2013.

Nicholson B. Differential Diagnosis:

Nociceptive and Neuropathic Pain.

The American Journal Gore M,

Brandenburg NA, Hoffman DL, Tai

KS, Stacey B. Burden of illness, 2008

Pain clinical up date , International

Association for The Study of Pain

(IASP) September 2010.

Sullivan MD, Robinson JP :

Antidepressant and anticonvulsant

medication for chronic pain; Physical

medicine and rehabilitation clinics of

north america 2006.

Sanchez LA, Pharmacoeconomic:

Principles, methods, and applications.

In: Pharmacotherapy a

pathophysiologic approach. 6th ed,

USA: McGraw-Hill; 2005

T. S. Hahm H.J Ahn, S.Ryu, MS Gwak

.Combined Gabapentine and

pregabalin therapy in a rat model of

neuropathic pain :British Journal of

Anaesthesia: 2012.

Treede RD, Jensen TS, Campbell JN,

Cruccu G . Redifinition of neuropathic

pain and a grading system for clinical

use: Consensus statement on clinical

and research diagnostic criteria.

Neurology. 2008.

Woolf CJ, Mannion RJ. Neuropathic pain:

aetiology, symptoms, mechanism, and

management, Lancet, 2004.

Wiffen PJ,Derry S, Moore RA, Mc Quay

HJ: Gabapentine for acute and chronic

pain in adults (review), The cochrane

library 2012, issue 8

Published
2018-03-01
How to Cite
Qiyaam, N., Adikusuma, W., Andayani, T. M., & endarti, D. (2018). ANALISIS EFEKTIVITAS DAN KUALITAS HIDUP (UTILITY) PENGGUNAAN GABAPENTIN PADA PASIEN NYERI NEUROPATIK POST STROKE DENGAN DIABETIK NEUROPATI DI RSUD PROVINSI NTB. Media Farmasi Indonesia, 13(1). Retrieved from https://mfi.stifar.ac.id/MFI/article/view/46